论文标题
药物诱导的整联蛋白αIIBBeta 3的激活导致较小的局部结构变化
Drug-induced activation of integrin alpha IIb beta 3 leads to minor localized structural changes
论文作者
论文摘要
整联蛋白是参与止血,伤口愈合,免疫和癌症的跨膜蛋白。响应细胞内信号和配体结合,整联蛋白采用不同的构象:弯曲(静止)形式;中间扩展形式;和配体占活性形式。进行这种构象动力学的整合素是异二聚体血小板受体alphaiibbeta3。尽管在激活过程中Alphaiibbeta3的整体结构的戏剧性重排可能与蛋白质二级结构的变化有关,但迄今尚未在膜环境中进行研究。在这里,我们检查了MN2+ - 和药物诱导的α33的激活以及对该蛋白质结构的影响,重构为脂质体。通过使用耗散监测和激活测定的石英晶体微量平衡,我们表明MN2+诱导构象特异性抗体PAC-1的结合,该抗体Pac-1仅识别扩展的活性整合素。然而,圆形二分法光谱表明,MN2+处理不会诱导αibbeta3的主要二级结构变化。同样,我们发现使用临床相关药物(例如奎宁)的治疗导致αibbeta3的激活,而没有蛋白质二级结构的显着变化。分子动力学仿真研究揭示了整联蛋白几个细胞外结构域的β-折叠概率的微小变化。我们的实验设置代表了一种在膜环境中研究跨膜蛋白(尤其是整联蛋白)的新方法,并为在临床相关条件下测试与整联蛋白结合的药物结合的新方法。
Integrins are transmembrane proteins involved in hemostasis, wound healing, immunity and cancer. In response to intracellular signals and ligand binding, integrins adopt different conformations: the bent (resting) form; the intermediate extended form; and the ligand-occupied active form. An integrin undergoing such conformational dynamics is the heterodimeric platelet receptor alphaIIbbeta3. Although the dramatic rearrangement of the overall structure of alphaIIbbeta3 during the activation process is potentially related to changes in the protein secondary structure, this has not been investigated so far in a membrane environment. Here we examine the Mn2+- and drug-induced activation of alphaIIbbeta3 and the impact on the structure of this protein reconstituted into liposomes. By quartz crystal microbalance with dissipation monitoring and activation assays we show that Mn2+ induces binding of the conformation-specific antibody PAC-1, which only recognizes the extended, active integrin. Circular dichroism spectroscopy reveals, however, that Mn2+-treatment does not induce major secondary structural changes of alphaIIbbeta3. Similarly, we found that treatment with clinically relevant drugs (e.g. quinine) led to the activation of alphaIIbbeta3 without significant changes in protein secondary structure. Molecular dynamics simulation studies revealed minor local changes in the beta-sheet probability of several extracellular domains of the integrin. Our experimental setup represents a new approach to study transmembrane proteins, especially integrins, in a membrane environment and opens a new way for testing drug binding to integrins under clinically relevant conditions.